Skip to main content
. 2014 Mar 4;15:27. doi: 10.1186/1471-2350-15-27

Table 7.

Patient characteristics (n = 180)

Characteristic  
Male gender
50% (90)
Age (months)
212 ± 15.75 (7–288)
Caucasoid
91.75%
BMI - thinness and accentuated thinness
22.22% (40)
One class I, II or III identified mutation
28.33% (51)
Two class I, II or III identified mutations
47.22% (85)
Age at first clinical manifestation (months)
35 ± 8.88 (0–156)
Age at diagnosis (months)
87 ± 13.63 (0–170.76)
Age at start of digestive symptoms (months)
40.6 ± 9.11 (0–149.4)
Age at start of pulmonary symptoms (months)
34.8 ± 9.88 (0–1156)
SpO2(%)
94.92 ± 4.26 (66–99)
Bhalla
8.74 ± 5.72 (0–25)
Kanga
18.85 ± 5.84 (10–40)
Shwachman-Kulczycki
65.85 ± 16.77 (20–95)
FVC(%)
79.29 ± 23.55 (19–135)
FEV1(%)
71.29 ± 27.467 (17–132)
FEV1/FVC(%)
83.46 ± 15.95 (37–137)
FEF25–75%
59.05 ± 35.55 (7–150)
Nasal polyps
18.33% (33)
Diabetes mellitus
18.33% (33)
Osteoporosis
16.11% (29)
Pancreatic insufficiency
80.0% (144)
Meconium ileus
15.00% (27)
Age at first isolated P. aeruginosa (months)
102.6 ± 14.45 (24–180)
P. aeruginosa statusa
56.67% (102)
P. aeruginosa mucoid statusa
42.22% (76)
B. cepacia statusa
13.88% (25)
A. xylosoxidans statusa
10.00% (18)
S. aureus statusa 78.88% (142)

Continuous variables expressed as mean ± SD (range). Other data shown as percentage (number of patients). aBased on three consecutive positive respiratory cultures.

N, Sample size; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital capacity; FEV1, Forced expiratory volume in the first second; FEF25–75, Forced expiratory flow between 25 and 75% of FVC.